FDLI makes leadership appointment
This article was originally published in Scrip
Executive Summary
The Food and Drug Law Institute (FDLI) has named former US FDA chief of staff Susan Winckler as the group's new president and CEO. She replaces James Kelley, who announced his departure in the summer. Ms Winckler is a pharmacist and attorney who served as FDA chief of staff from January 2007 to June 2009. She was most recently managing director of the medical products practice at Leavitt Partners, a consulting firm headed by former Health and Human Services secretary Mike Leavitt.
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.